Electrochemical Carbamazepine Aptasensor for Therapeutic Drug Monitoring at the Point of Care.

Autor: Chung S; Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California 92093, United States., Singh NK; Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California 92093, United States., Gribkoff VK; Mensura Health, Weston, Massachusetts 02493, United States., Hall DA; Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California 92093, United States.; Department of Bioengineering, University of California San Diego, La Jolla, California 92093, United States.
Jazyk: angličtina
Zdroj: ACS omega [ACS Omega] 2022 Oct 17; Vol. 7 (43), pp. 39097-39106. Date of Electronic Publication: 2022 Oct 17 (Print Publication: 2022).
DOI: 10.1021/acsomega.2c04865
Abstrakt: Monitoring the anti-epileptic drug carbamazepine (CBZ) is crucial for proper dosing, optimizing a patient's clinical outcome, and managing their medication regimen. Due to its narrow therapeutic window and concentration-related toxicity, CBZ is prescribed and monitored in a highly personalized manner. We report an electrochemical conformation-changing aptasensor with two assay formats: a 30 min assay for routine monitoring and a 5 min assay for rapid emergency testing. To enable "sample-to-answer" testing, a de novo CBZ aptamer ( K d < 12 nM) with conformational switching due to a G-quadruplex motif was labeled with methylene blue and immobilized on a gold electrode. The electrode fabrication and detection conditions were optimized using electrochemical techniques and visualized by atomic force microscopy (AFM). The aptasensor performance, including reproducibility, stability, and interference, was characterized using electrochemical impedance spectroscopy and voltammetry techniques. The aptasensor exhibited a wide dynamic range in buffer (10 nM to 100 μM) with limits of detection of 1.25 and 1.82 nM for the 5 and 30 min assays, respectively. The clinical applicability is demonstrated by detecting CBZ in finger prick blood samples (<50 μL). The proposed assays provide a promising method to enable point-of-care monitoring for timely personalized CBZ dosing.
Competing Interests: The authors declare the following competing financial interest(s): Mensura Health employs V.K.G., and Mensura Health has filed IP on the reported aptamer.
(© 2022 The Authors. Published by American Chemical Society.)
Databáze: MEDLINE
Externí odkaz: